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Abstract
Aims To assess the metabolic health of obese and non-obese women at high GDM risk 5 years postpartum.
Methods This is a secondary analysis of the 5-year follow-up of the RADIEL GDM prevention study including 333 women 
at high GDM risk (BMI ≥ 30 kg/m2 and/or previous GDM). Five years postpartum metabolic health was assessed including 
anthropometric measurements, oral glucose tolerance test, lipid metabolism, and body composition as well as medical history 
questionnaires. For the analysis, we divided the women into four groups based on parity, BMI, and previous history of GDM.
Results Five years postpartum impaired glucose regulation (IFG, IGT, or diabetes) was diagnosed in 15% of the women; 
3.6% had type 2 diabetes. The highest prevalence was observed among obese women with a history of GDM (26%), and the 
lowest prevalence (8%) among primiparous obese women (p = 0.021). At follow-up 25–39% of the obese women fulfilled 
the diagnostic criteria for the metabolic syndrome, in the non-obese group 11% (p < 0.001). This was associated with body 
fat percentage. The non-obese group, however, faced metabolic disturbances (IFG, IGT, diabetes, or metabolic syndrome) 
at a significantly lower BMI (p < 0.001). Among women who were non-obese before pregnancy, 5 years postpartum, the 
obesity prevalence based on BMI was 14% and based on body fat percentage 58%.
Conclusions The prevalence of impaired glucose regulation and metabolic syndrome is high 5 years postpartum among 
women at high risk of GDM. There are high-risk women also among the non-obese, who develop metabolic derangements 
already at a lower BMI.
Clinical trial registration ClinicalTrials.gov, www.clini caltr ials.com, NCT01698385.
Keywords Gestational diabetes · Type 2 diabetes · Metabolic syndrome · Heterogeneity · Normal weight obesity · Body 
composition
Introduction
Globally, the prevalence of obesity and consequently that 
of type 2 diabetes is increasing in epidemic proportions. 
Along with the escalating trend in obesity, there is a similar 
increase in the prevalence of gestational diabetes (GDM), 
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which in 2016 in Finland reached 18% [1]. Obesity, how-
ever, is not the only risk factor for GDM. Other risk factors 
include advanced age, family history of diabetes, parity, non-
Caucasian ethnicity, previous macrosomia, and history of 
GDM [2].
Type 2 diabetes is known to have multiple underlying 
pathophysiological mechanisms [3], and the same is true for 
GDM. The heterogeneity of GDM, however, has received 
less interest. Already in the 1980s, studies demonstrated dif-
ferences among women with GDM in insulin secretion, insu-
lin sensitivity, autoimmunity, and adiposity [4, 5]. Women 
with GDM can be grouped according to their insulin sensi-
tivity and insulin secretion profile; 50% are mainly insulin 
resistant, and 30% have an impairment in their insulin secre-
tion, while the rest have a combination [6]. Our previous 
findings have highlighted the heterogeneity of GDM; non-
obese participants with a history of GDM had the highest 
incidence of GDM, despite being metabolically healthy in 
the first trimester [7].
Women with a history of GDM are at a seven times higher 
risk of developing type 2 diabetes, the metabolic syndrome, 
and cardiovascular disease later in life [8–12]. Previous 
follow-up studies, however, have primarily been performed 
in an obese population, or the analyses have not taken into 
account the heterogeneity of GDM. Non-obese women 
with GDM have an altered insulin secretion profile during 
pregnancy [13], which is still evident 5 years after delivery 
[14]. To our knowledge, there are no other published studies 
focusing on the long-term cardio-metabolic risk profile of 
non-obese women with a history of GDM.
The aim of this study was to assess the future risk of 
metabolic disturbances among women in the RADIEL 
study—i.e., women at high GDM risk—taking into account 
the heterogeneity of GDM.
Methods
Study design
This is a secondary analysis of women participating in the 
RADIEL follow-up study, a prospective observational cohort 
study conducted in Helsinki and Lappeenranta (2013–2017). 
The original RADIEL study [15] was a GDM prevention 
study focusing upon women at high GDM risk, conducted in 
Finland (2008–2014) in the three maternity hospitals in the 
Helsinki area (University Hospital of Helsinki HUH, Jorvi 
Hospital, and Kätilöopisto Maternity Hospital) and in the 
South Karelian Central Hospital (SKCH) in Lappeenranta. 
In total 720 women were recruited either before or in early 
pregnancy and randomized to either lifestyle intervention 
or a control group. Previous publications [15, 16] have pre-
sented the details of the original intervention study.
Participants with a live birth, and their children, were 
invited to a follow-up visit 4–6 years after delivery. In this 
study, they comprised a cohort at high diabetes risk without 
considering the previous assignment into an intervention or 
a control group.
Participants
Originally the RADIEL study included women who were 
18 years of age or older, with a BMI ≥ 30 kg/m2 and/or 
a history of GDM in a previous pregnancy. Exclusion cri-
teria were current diabetes, medications altering glucose 
metabolism, multiple pregnancy, severe psychiatric prob-
lems, physical disabilities, and communication problems 
based on inadequate language skills. Among the partici-
pants, 228 entered the study in pre-pregnancy and 492 in 
early pregnancy before 20 gestational weeks. In total 348 
women participated in the follow-up, but in this study, we 
included those 333 women who attended an oral glucose 
tolerance test (OGTT) or had a physician-diagnosed diabe-
tes after the index pregnancy. All participants gave written 
informed consent and the Ethics Committees of HUH and 
SKCH approved the study design.
Outcomes
The main outcome was the cumulative incidence of 
impairment in glucose regulation. A secondary outcome 
was presence of the metabolic syndrome and its com-
ponents. Diagnosis of diabetes was either self-reported 
(diagnosed by a physician and/or use of antidiabetic 
drugs) or based on the following laboratory tests: fasting 
plasma glucose ≥ 7.0 mmol/l or 2-h glucose in a 2-h 75 g 
OGTT ≥ 11.1 mmol/l. Impaired glucose tolerance (IGT) was 
defined as 2-h glucose 7.8–11.0 mmol/l and impaired fast-
ing glucose (IFG) as fasting plasma glucose 6.1–6.9 mmol/l. 
Meeting the criteria for either IFG, IGT, or type 2 diabe-
tes resulted in the composite outcome of impaired glucose 
regulation. In addition to glucose metabolism, the laboratory 
tests performed in conjunction with the study visit included 
assessment of insulin, glycated hemoglobin, lipids (cho-
lesterol, triglycerides, LDL cholesterol, and HDL choles-
terol), thyroid function (TSH and free thyroxine), alanine 
aminotransferase, and highly sensitive C-reactive protein. 
In the analysis of hs-CRP, we excluded values exceeding 
10 mmol/l. Previous reports include description of the meth-
ods used for laboratory analysis [7].
For assessing the metabolic syndrome, we used the 
National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP/ATP III) criteria [17]. Meeting 
three out of five criteria resulted in the diagnosis of the 
metabolic syndrome: waist circumference > 88 cm, fasting 
plasma glucose ≥ 5.6 mmol/l, triglycerides ≥ 1.7 mmol/l, 
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HDL  <  1.29  mmol/l,  and systolic blood pres-
sure > 130 mmHg or diastolic blood pressure > 85 mmHg. 
Additional markers were the use of medication influencing 
blood pressure, HDL, or triglyceride levels. We also ana-
lyzed a composite metabolic outcome defined as having 
either impaired glucose regulation (IFG, IGT, or type 2 
diabetes) and/or metabolic syndrome.
The study visit included anthropometric measurements 
as well as assessment of blood pressure in the sitting posi-
tion from the right arm with a sphygmomanometer. Body 
composition was assessed by a multi-frequency bio-imped-
ance measurement method (InBody3.0, Biospace Co., Ltd, 
Seoul, Korea) [18]. American Council on exercise guide-
lines [19] provided the definition of obesity based on body 
fat percentage of 32% or over. Questionnaires provided 
data on chronic diseases, regular medications, and family 
history of diabetes. Educational attainment was reported 
as years of education. Alcohol consumption and smok-
ing were self-reported as well as physical activity, which 
was reported as duration of moderately strenuous physical 
activity in minutes per week.
For the analysis of this study, we divided the partici-
pants into four groups (A, B, C, D) according to their pre-
pregnancy BMI, parity, and GDM history before the index 
pregnancy, similarly to our previous study [7]. Group A: 
obese primiparous women, group B: multiparous obese 
women without GDM history, group C: multiparous non-
obese women with previous GDM, and group D: mul-
tiparous obese women with previous GDM. Diagnosis of 
GDM in the index pregnancy was based on a 2-h 75 g 
OGTT either in the first or second trimester with diag-
nostic thresholds of 5.3–10.0–8.6 mmol/l (0, 1 and 2 h).
Statistics
Continuous data are presented as means with standard 
deviations (SD) or as medians with interquartile range 
(IQR). Counts with percentages are reported for frequen-
cies. Between-group comparisons were made using analy-
sis of variance (ANOVA) and the Kruskal–Wallis test for 
continuous variables and using Chi-squared tests for cat-
egorical variables. When using adjusted models, analysis 
of covariance or logistic regression model was applied. 
In the case of violation of the assumptions (e.g., non-nor-
mality), a bootstrap-type test was used (10,000 replica-
tions). The normality of the variables was tested using the 
Shapiro–Wilk W test. The adjustment for multiplicity was 
performed by Hommel’s multiple comparison procedure 
to identify significant differences in at least one of the 
two between-group comparisons (p = 0.05) if needed. All 
analyses were performed using STATA software (version 
14.0, StataCorp, LP, TX).
Results
In total 333 women were included in this study. Median 
follow-up time after delivery was 65 months (IQR 62–68) 
with no difference between the groups. GDM was diag-
nosed in the index pregnancy in 33% of the women in 
group A, in 25% in group B, in 60% in group C, and in 
66% in group D. Weight change during follow-up was 
similar in all groups (p = 0.90), and it was not associ-
ated with GDM status of the index pregnancy (p = 0.42), 
(interaction p = 0.95).
Table  1 presents the baseline characteristics of the 
participants in the first trimester of the index pregnancy 
according to previously defined groups based on parity, 
pre-pregnancy BMI, and history of GDM (A, B, C, and D). 
These groups showed marked differences in the parameters 
related to metabolic health. In general, both in the first 
trimester and 5 years postpartum, women belonging to 
group C (defined as non-obese women with GDM prior to 
the index pregnancy) were metabolically healthier, except 
for their glucose metabolism.
At follow-up, 3.6% of the women were diagnosed with 
diabetes and altogether 15% of the women had impaired 
glucose regulation (IFG/IGT/diabetes) (Fig. 1). The high-
est prevalence of abnormalities in glucose metabolism was 
observed in group D (26%), and it was significantly dif-
ferent from group A (8%) (p = 0.021) after adjustment for 
age and educational attainment. Marked differences were 
observable at follow-up between the groups in the assessed 
metabolic parameters (Table 2).
Women with GDM in the index pregnancy had higher 
fasting and 2-h glucose concentrations as well as  HbA1c 
compared to those with normal glucose tolerance. There 
was no interaction between history of GDM and ABCD 
grouping (supplementary figure).
Metabolic syndrome was present in 32% of the par-
ticipants in group A, in 25% in group B, in 11% in group 
C, and in 39% in group D (p < 0.001, adjusted for age 
and educational attainment). The difference was localized 
between group C and the other groups (p < 0.001). Fig-
ure 2 shows the prevalence of the individual pathologi-
cal components of the metabolic syndrome according to 
ABCD grouping. Prevalence of the composite metabolic 
outcome defined as either impaired glucose regulation and/
or metabolic syndrome was similar between the groups 
(p = 0.24, adjusted for age and educational attainment).
Women with metabolic disturbances at follow-up had a 
higher BMI compared to those considered metabolically 
healthy (Fig. 3). Women in group C showed metabolic 
disturbances at a significantly lower BMI than women in 
the other groups; in all groups, the metabolic syndrome 
was associated with higher body fat percentage (Fig. 4). 
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The prevalence of obesity defined according to body fat 
percentage (i.e., ≥ 32%) was lowest among participants in 
group C (prevalence 58%, p < 0.001).
Discussion
At 5 years postpartum, the cumulative incidence of impaired 
glucose regulation among these high-risk women was 15%. 
The highest prevalence was seen in obese women with a 
history of GDM before the index pregnancy. They were 
additionally at high risk of the metabolic syndrome; the inci-
dence 5 years postpartum was 39%. As anticipated, women 
with GDM during the index pregnancy had at follow-up 
higher glucose concentrations during the OGTT. Overall, the 
prevalence of impaired glucose regulation was high. History 
of GDM before the index pregnancy seemed to be a more 
important risk factor for impaired glucose regulation than 
degree of adiposity based on BMI.
The original RADIEL study included a group of non-
obese women with a history of GDM, who despite being 
metabolically healthier at first trimester of pregnancy, 
showed a high recurrence of GDM, i.e., 60%. At 5 years 
postpartum, they showed additionally a high prevalence 
(18%) of derangements in glucose metabolism, despite an 
otherwise rather normal metabolic profile. The cumulative 
incidence of metabolic syndrome was lower than in the 
other groups. The women belonging to this group devel-
oped, however, metabolic derangements at a significantly 
lower BMI and with a lower body fat percentage compared 
to the other groups. Diabetes-related autoantibodies meas-
ured in the first trimester did not provide an explanation to 
the high GDM incidence [7].
The future risk of diabetes among women with a his-
tory of GDM varies according to study design, population, 
ethnicity, and diagnostic criteria. A 5-year follow-up [20] 
on women with GDM based on IADPSG criteria reported 
a 26% cumulative incidence of prediabetes or diabetes. 
The cumulative incidence in our study reached 23% among 
women with GDM in the index pregnancy. In Sweden, 
where cut-offs for GDM diagnosis are markedly higher, 
Table 1  Baseline characteristics of the study participants in the first trimester of the index pregnancy according to groups based on parity, BMI, 
and history of GDM
Data are presented as mean values (standard deviation, SD), unless otherwise indicated
Group A, primiparous BMI ≥ 30 kg/m2; Group B, multiparous, BMI ≥ 30 kg/m2, no history of GDM; Group C, multiparous, BMI < 30 kg/m2, 
history of GDM; Group D, multiparous, BMI ≥ 30 kg/m2, history of GDM
A
N = 91
B
N = 63
C
N = 117
D
N = 62
p value
History of GDM No No Yes Yes
Age (years) 32 (5) 34 (4) 34 (4) 35 (5) 0.002
Own birth weight (g) 3620 (495) 3536 (505) 3416 (541) 3433 (570) 0.041
BMI (kg/m2) pre-pregnancy 34.3 (3.7) 34.2 (3.9) 24.4 (2.6) 34.3 (4.8) < 0.001
Educational attainment (years) 14.9 (1.8) 14.2 (2.0) 15.0 (2.0) 14.2 (2.1) 0.012
Family history of DM, n (%) 27 (30) 14 (24) 43 (37) 21 (35) 0.32
Smoking, n (%) 3 (3) 4 (6) 5 (4) 1 (2) 0.57
Alcohol use portion per week, mean (SD) 0.09 (0.37) 0.07 (0.24) 0.46 (0.91) 0.27 (0.61) < 0.001
Physical activity (min/week), median (IQR) 60 (30, 120) 80 (30, 140) 90 (30, 135) 60 (30, 150) 0.78
Total triglycerides (mmol/l) 1.31 (0.52) 1.33 (0.51) 1.13 (0.36) 1.45 (0.54) < 0.001
LDL cholesterol (mmol/l) 2.67 (0.64) 2.98 (0.84) 2.66 (0.70) 2.91 (0.77) 0.023
HDL cholesterol (mmol/l) 1.66 (0.32) 1.71 (0.30) 1.74 (0.33) 1.62 (0.33) 0.11
Total cholesterol (mmol/l) 4.74 (0.74) 4.99 (1.05) 4.72 (0.87) 5.06 (0.92) 0.054
hs-CRP (mmol/l) 8.0 (6.5) 8.7 (7.6) 4.5 (6.6) 9.4 (7.9) < 0.001
HbA1c (mmol/mol) 33.4 (3.2) 34.4 (3.4) 34.2 (3.0) 35.4 (3.4) 0.009
HbA1c (%) 5.21 (0.29) 5.30 (0.31) 5.28 (0.27) 5.39 (0.31)
Fasting plasma glucose (mmol/l) 4.99 (0.39) 4.96 (0.38) 5.10 (0.41) 5.30 (0.37) < 0.001
Fasting plasma insulin (mU/l) 10.61 (6.46) 8.25 (3.32) 5.52 (3.40) 9.81 (4.76) < 0.001
2-h glucose in OGTT (mmol/l) 6.14 (1.19) 6.15 (1.21) 6.20 (1.47) 6.19 (1.22) 0.99
ALAT (U/l) 27 (20) 20 (12) 14 (5) 16 (8) < 0.001
Blood pressure
 Systolic (mmHg) 122 (12) 122 (12) 114 (12) 123 (13) < 0.001
 Diastolic (mmHg) 79 (8) 78 (8) 72 (8) 77 (11) < 0.001
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30% developed diabetes already 5 years postpartum and 
51% had some form of impaired glucose metabolism [21].
Many studies have assessed the determinants of future 
diabetes risk in women with prior GDM. A systematic 
review [22] demonstrated higher risk ratios for BMI, family 
history of diabetes, certain ethnicities, age, multiparity, early 
onset of GDM, fasting blood glucose, and  HbA1c, as well as 
insulin use and hypertension during pregnancy. Based on a 
German study including 304 women, Köhler and colleagues 
created a risk score for predicting risk of diabetes after GDM 
[23]. Risk markers included BMI, insulin treatment of GDM, 
family history of diabetes, and lactation, and the C-statistic 
reached 0.75. Additionally, severity of glucose intolerance 
during pregnancy seems to be associated with later risk of 
type 2 diabetes [20, 24]. Although many studies highlight an 
elevated risk for type 2 diabetes with increasing adiposity, 
our study demonstrates that there are high-risk individuals 
also among the non-obese. Findings from the US Nurses’ 
Health Study similarly indicate an increase in diabetes risk 
already among women with normal BMI [25].
In addition to being susceptible for type 2 diabetes, 
women with a history of GDM are also at high risk of the 
metabolic syndrome; 5 years after delivery it was diagnosed 
in one-fourth of the women in our study. One year after 
delivery in a cohort similar to the RADIEL study [9], the 
incidence of metabolic syndrome was 16%. Another study 
[10] reported increasing rates according to 1 or 2 patho-
logical values in OGTT during pregnancy: in the 10-year 
Group
A B C D
Pr
ev
al
en
ce
, %
0
5
10
15
20
25
30
35
40
45
50
IFG
Group
A B C D
IGT
Group
A B C D
DM
Group
A B C D
Total
Fig. 1  Prevalence of IFG, IGT, and type 2 diabetes according to 
ABCD grouping as well as the overall prevalence of impairment in 
glucose regulation (p = 0.013). Group A: primiparous BMI ≥ 30 kg/
m2. Group B: multiparous, BMI  ≥  30  kg/m2, no history of GDM. 
Group C: multiparous, BMI < 30 kg/m2, history of GDM. Group D: 
multiparous, BMI ≥ 30 kg/m2, history of GDM
Table 2  Metabolic characteristics of the participants in the A, B, C, and D groups 5 years postpartum
Data are presented as mean values (standard deviation, SD), unless otherwise indicated
Group A, primiparous BMI ≥ 30 kg/m2; Group B, multiparous, BMI ≥ 30 kg/m2, no history of GDM; Group C, multiparous, BMI < 30 kg/m2, 
history of GDM; Group D, multiparous, BMI ≥ 30 kg/m2, history of GDM
A
N = 91
B
N = 63
C
N = 117
D
N = 62
p value
BMI (kg/m2) 35.4 (5.0) 35.1 (5.8) 25.5 (3.7) 35.4 (5.4) < 0.001
Waist (cm) 113 (14) 112 (15) 91 (11) 113 (13) < 0.001
Total triglycerides (mmol/l) 1.1 (0.55) 1.00 (0.42) 0.89 (0.53) 1.13 (0.66) 0.021
LDL cholesterol (mmol/l) 2.86 (0.68) 3.12 (0.91) 2.97 (0.73) 3.03 (0.73) 0.20
HDL cholesterol (mmol/l) 1.37 (0.34) 1.44 (0.32) 1.62 (0.34) 1.41 (0.35) < 0.001
hs-CRP (mmol/l) 2.50 (2.07) 2.61 (2.26) 1.19 (1.40) 2.20 (1.73) < 0.001
HbA1c (mmol/mol) 34.6 (3.1) 35.8 (3.6) 35.6 (3.3) 38.0 (10.2) 0.007
HbA1c (%) 5.32 (0.28) 5.43 (0.33) 5.41 (0.30) 5.63 (0.93)
Fasting plasma glucose (mmol/l) 5.07 (0.48) 5.07 (0.49) 5.30 (0.53) 5.67 (1.81) < 0.001
Fasting plasma insulin (mU/l) 13.52 (8.55) 12.67 (7.11) 8.14 (5.31) 13.69 (8.44) < 0.001
Blood pressure
 Systolic (mmHg) 127 (13) 127 (13) 117 (11) 127 (15) < 0.001
 Diastolic (mmHg) 80 (10) 80 (9) 74 (8) 81 (10) < 0.001
Physical activity (min/week), median (IQR) 60 (30, 180) 60 (30, 120) 85 (50, 160) 110 (30, 180) 0.56
Medication for hypertension, n (%) 6 (7) 2 (3) 3 (3) 6 (10) 0.16
Medication for dyslipidemia, n (%) 0 (0) 1 (2) 3 (3) 0 (0) 0.41
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follow-up, the rates were 46 and 63%, respectively. The 
importance of the metabolic syndrome lies in its associa-
tion with future risk of cardiovascular disease and type 2 
diabetes [16, 26]. Although metabolic disturbances during 
early postpartum period are associated with future diabetes 
risk [27], in our study the non-obese high-risk women were 
metabolically healthy both early in pregnancy as well as 
5 years postpartum, except for their glucose metabolism. 
This suggests that there is heterogeneity in the pathophysi-
ology concerning both GDM and the future development 
of diabetes.
Both type 2 diabetes and the metabolic syndrome are 
strongly associated with adiposity [28], and correspondingly 
our results demonstrate an association between metabolic 
syndrome and higher body fat percentage. This concerns 
also the normal weight population [29], and therefore BMI 
should not be the only marker of adiposity when assessing 
the cardiovascular risk profile. In our study, waist circum-
ference correlated more strongly with body fat percentage 
than BMI, especially in the non-obese group. Unfortunately, 
we can only speculate on the amount of visceral adiposity 
based on waist circumference, which in group C was above 
the 88 cm limit among 58% of the participants.
Among the group C participants, who were non-obese 
before the index pregnancy, prevalence of obesity at 5-year 
follow-up based on BMI was 14%. The prevalence of obe-
sity based on body fat percentage, however, was 58%. This 
resembles “normal weight obesity” (NWO) [30], defined 
commonly as BMI in the normal range (18.5–24.9 kg/m2) 
Fig. 2  Components of the meta-
bolic syndrome according to the 
National Cholesterol Educa-
tion Program Adult Treatment 
Panel III (ATP III) in ABCD 
groups. Group A: primiparous 
BMI ≥ 30 kg/m2. Group B: 
multiparous, BMI ≥ 30 kg/
m2, no history of GDM. Group 
C: multiparous, BMI < 30 kg/
m2, history of GDM. Group D: 
multiparous, BMI ≥ 30 kg/m2, 
history of GDM
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Fig. 3  Body mass index (BMI) 
in women according to pres-
ence of metabolic disturbances 
(MD+) postpartum (IFG, IGT, 
T2D, or MetS) and in women 
without metabolic disturbances 
(MD−) based upon ABCD 
grouping. Group A: primipa-
rous BMI ≥ 30 kg/m2. Group 
B: multiparous, BMI ≥ 30 kg/
m2, no history of GDM. Group 
C: multiparous, BMI < 30 kg/
m2, history of GDM. Group D: 
multiparous, BMI ≥ 30 kg/m2, 
history of GDM
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Fig. 4  A. Relationship between 
body fat percentage and diag-
nosis of metabolic syndrome in 
ABCD groups. MetS p < 0.001, 
group p < 0.001, interaction 
p = 0.06. B. Prevalence of 
obesity according to body fat 
percentage ≥ 32% in ABCD 
groups. p < 0.001. Group A: 
primiparous BMI ≥ 30 kg/
m2. Group B: multiparous, 
BMI ≥ 30 kg/m2, no history of 
GDM. Group C: multiparous, 
BMI < 30 kg/m2, history of 
GDM. Group D: multiparous, 
BMI ≥ 30 kg/m2, history of 
GDM
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and body fat percentage above normal (≥ 32%). The NWO 
prevalence rates range from 0.1 to 41.1% [30], depend-
ing on the criteria applied. Studies have demonstrated 
associations between NWO and insulin resistance, high 
blood pressure, dyslipidemia, and increased risk of car-
diovascular disease and type 2 diabetes, while showing 
no typical signs of chronic inflammation usually associ-
ated with obesity [31, 32]. According to Lorenzo [33], 
this condition could be the “pro-inflammatory step” to the 
chronic inflammatory state of obesity. In our study these 
NWO women showed merely derangements in their glu-
cose metabolism.
One of the proposed underlying causes explaining the 
elevated diabetes risk observed in GDM women is impaired 
insulin secretion [34]. Interestingly, during pregnancy secre-
tory defects are more characteristic in normal weight women 
whereas obese women are more frequently insulin resist-
ant [6]. To our knowledge, there are no longitudinal studies 
focusing on future diabetes risk in non-obese women with 
prior GDM. Damm and his colleagues demonstrated that the 
reduced and delayed insulin secretory profile observed in 
non-obese women during pregnancy persisted 5 years post-
partum [14]. We have similarly shown that the non-obese 
women with GDM are at high risk of type 2 diabetes and 
to a lesser degree also for metabolic syndrome, already at a 
significantly lower BMI.
We hypothesize that there could be a common underly-
ing denominator for GDM and type 2 diabetes not based 
purely on adiposity. Genetic predisposition and gut micro-
biota are potential underlying factors, but also intrauterine 
programming [35, 36] could offer an explanation. Metabolic 
memory extends from intrauterine life into adulthood [37] 
and women born small for gestational age tend to have a 
higher body fat percentage regardless of their BMI [38, 39]. 
Maternal diet, physical activity, hyperglycemia, adiposity, 
and stress can affect fetal size, body composition, and risk 
of non-communicable diseases later in life [36]. Supporting 
this hypothesis, the women in groups C and D, with highest 
prevalence of glycemic disturbances, had lower birth weight 
compared to the other groups.
The potential long-term consequences of fetal program-
ming [40] are not the only reason for the importance of 
diagnosing GDM in non-obese women. Frequently, history 
of GDM is the only marker of increased diabetes risk in 
these women. Therefore, IADPSG and WHO recommend 
universal screening [41], but as the EBCOG report [42] 
shows, strategies vary highly even inside Europe. Many 
countries use risk factor-based screening focusing primar-
ily on obese women, certain ethnic groups, or women with 
history of macrosomia, GDM, or family history of diabetes. 
This approach seems insufficient [43], but it reflects both 
financial issues and also the underestimated consequences 
of GDM in non-obese women.
Strengths of this study include the relatively high num-
ber of participants and inclusion of non-obese women. We 
have detailed knowledge on the metabolic status during 
pregnancy, creating excellent opportunities for long-term 
follow-up. The lack of a control group of non-obese women 
without previous GDM can be considered a weakness of the 
study. Additionally, we do not have data on diabetes-related 
autoantibodies at follow-up. We also lack more sophisticated 
measures of insulin secretion and insulin sensitivity. Further, 
all participants were of Caucasian origin, limiting the gen-
eralizability to other populations.
Based on our results, postpartum follow-up should not 
exclude non-obese women as they are also at high risk of 
diabetes. Current screening strategies need further strength-
ening since they are rather suboptimal in most countries [44, 
45]. Future studies need to further investigate the underly-
ing pathophysiology of GDM in non-obese women and aim 
at creating preventive strategies tailored for them. As they 
seldom show easily identifiable risk factors, this emphasizes 
in accordance to IADPSG guidelines, the need for universal 
GDM screening. Early diagnosis, improved identification of 
non-obese individuals at risk, and preferably early preven-
tive strategies are needed to fight the epidemic of diabetes.
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